All In Biotech

Drug Trial Radar · NCT00099242

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Oct 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,040 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,040

Actual

Start

Nov 2003

Primary completion

Not stated

Study completion Jan 2006

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 10, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.

Conditions

  • Alzheimer's Disease
  • Dementia, Alzheimer Type

Interventions

  • rivastigmine transdermal patchDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in cognition from baseline at week 24
  2. Global clinical impression of change from baseline at week 24

Locations

75 sites in 21 countries. Site status is shown where the registry gives one.

  • Site not named

    Orange, California

  • Site not named

    San Francisco, California

  • Site not named

    Boca Raton, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    Port Charlotte, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Snellville, Georgia

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Long Branch, New Jersey

  • Site not named

    Toms River, New Jersey

  • Site not named

    Whiting, New Jersey

  • Site not named

    Columbus, Ohio

  • Site not named

    Dayton, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Greensburg, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Tacoma, Washington

  • Site not named

    Santiago, Chile

  • Site not named

    Valparaíso, Chile

  • Site not named

    Brno, Czechia

  • Site not named

    Brno-Bohunice, Czechia

  • Site not named

    Hradec Králové, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Glostrup Municipality, Denmark

  • Site not named

    Hillerød, Denmark

  • Site not named

    Kuopio, Finland

  • Site not named

    Investigative Sites, Germany

  • Site not named

    Guatemala City, Guatemala

  • Site not named

    Beersheva, Israel

  • Site not named

    Haifa, Israel

  • Site not named

    Jerusalem, Israel

  • Site not named

    Petah Tikva, Israel

  • Site not named

    Tel Aviv, Israel

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.